Physician profile
Norma Jacquez
NPI 1013593029
$2,035.02
in general payments reported to CMS, 2019-2025
29 companies · $170 in 2025
The $170 reported for 2025 was less than what a typical Primary Care provider received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,069 · 2022: $783 · 2023: $12.84 · 2025: $170.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $183.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $182.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $359.50 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $198.88 | 2022 | |
| Glaxosmithkline, LLC. | $198.62 | 2021-2022 | |
| Novo Nordisk INC | $157.79 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $128.63 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $110.82 | 2025 | Caplyta |
| Astrazeneca Pharmaceuticals LP | $97.62 | 2021-2022 | |
| Lilly USA, LLC | $90.21 | 2021-2022 | |
| Radius Health, INC. | $79.16 | 2021-2022 | |
| Amarin Pharma, INC. | $76.96 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $66.99 | 2021 | |
| Pfizer INC. | $60.91 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $54.60 | 2021-2022 | |
| Neurelis, INC. | $50.00 | 2022 | |
| Dexcom, INC. | $42.56 | 2021-2023 | Dexcom G6 Transmitter |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $30.97 | 2021-2022 | |
| Amgen INC. | $23.78 | 2022 | |
| Alkermes, INC. | $23.19 | 2025 | Aristada, Lybalvi |
| Xeris Pharmaceuticals, INC. | $22.57 | 2021 | |
| Janssen Pharmaceuticals, INC | $22.04 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $21.49 | 2025 | Trintellix |
| Esperion Therapeutics, INC. | $19.67 | 2021 | |
| Sanofi-Aventis U.S. LLC | $16.19 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.32 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $14.28 | 2025 | Austedo Xr |
| Arbor Pharmaceuticals, INC. | $14.08 | 2022 | |
| Merck Sharp & Dohme LLC | $13.42 | 2022 | |
| Allergan, INC. | $12.73 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.04 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Norma Jacquez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.